证券代码：301096 证券简称：百诚医药 公告编号：2023-025 杭州百诚医药科技股份有限公司 第三届董事会第十四次会议决议公告 本公司全体董事、高级管理人员保证公告内容的真实、准确和完整，并对公 告中的虚假记载、误导性陈述或者重大遗漏承担责任。 一、董事会会议召开情况 杭州百诚医药科技股份有限公司（以下简称"公司"）第三届董事会第十四次 会议于 2023 年 8 月 8 日（星期二）在公司会议室以现场结合通讯的方式召开。 会议通知已于 2023 年 7 月 29 日通过电话、邮件的方式送达各位董事。本次会议 应出席董事 9 人，实际出席董事 9 人（其中：独立董事胡永洲先生、李会林女士、 任成先生以通讯方式出席）。 会议由董事长楼金芳女士主持，监事、高级管理人员列席会议。会议召开符 合有关法律、法规、规章和《公司章程》的规定。经各位董事认真审议，会议形 成了如下决议： 二、董事会会议审议情况 特此公告。 经审议，董事会认为：公司 2023 年半年度报告全文及其摘要的内容真实、 准确、完整地反映了公司 2023 年半年度经营的实际情况，不存在任何虚假记 载、误导性陈述或者重大遗漏；报告编制和审核的程序符 ...

一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0次 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于防止 | | | 关联方占用公司资源的制度、募集资金管理制度、内控制 | 是 | | 度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6次 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4、公司治理督导情况 | | | （1）列席公司股东大会次数 | 本年度内未列席 | | （2）列席公司董事会次数 | 本年度内未列席 | | （3）列席公司监事会次数 | 本年度内未列席 | | 5、现场检查情况 | | | （1）现场检查次数 | 0次 | | （2）现场检查报告是否按照本所规定报送 | 不适用 | | （3）现场检查发现的主要问题及整 ...

杭州百诚医药科技股份有限公司 根据中国证监会《上市公司监管指引第 8 号——上市公司资金往来、对外担 保的监管要求》、《深圳证券交易所创业板股票上市规则》及《公司章程》等相关 规定和要求，我们对公司报告期内控股股东及其他关联方占用公司资金情况进行 了认真的核查，报告期内公司不存在控股股东及其他关联方违规占用公司资金的 情况，也不存在以前期间发生延续至报告期的控股股东及其他关联方违规占用公 司资金的情况。 三、关于公司对外担保情况的独立意见及专项说明 根据《上市公司监管指引第 8 号--上市公司资金往来、对外担保的监管要求》 等相关规定，经核查，报告期内，除对合并报表范围的子公司担保外，公司不存 在为控股股东、实际控制人及其关联方、任何非法人单位或个人提供担保的情况， 不存在违规担保的情况。 （以下无正文） （此页无正文，为《杭州百诚医药科技股份有限公司独立董事关于第三届董 事会第十四次会议相关事项的独立意见》之签字页） 胡永洲 相关事项的独立意见 根据《上市公司独立董事规则》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》以及 《公司章程》等相关 ...

编制单位：杭州百诚医药科技股份有限公司 单位：人民币万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司 | 上市公司核算 | 2023 年期初占 | 2023 年半年度占 | 2023 半年度占 | 2023 半年度 | 2023 年上年 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 的关联关系 | 的会计科目 | 用资金余额 | 用累计发生金额 | 用资金的利息 | 偿还累计发 | 末占用资金余 | | | | | | | | | （不含利息） | （如有） | 生金额 | 额 | | | | 控股股东、实际控制人 | | | | | | | | | | 非经营性占用 | | 及其附属企业 | | | | | | | | | | 非经营性占用 | | 小 计 | - | - | - | | | | | | | - | | 前控股股东、实际控制 | | | | | | | | | | 非经营性占用 | | 人及其附属企业 | | | | | | | | | ...

本公司全体监事保证公告内容的真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 一、监事会会议召开情况 杭州百诚医药科技股份有限公司（以下简称"公司"）第三届监事会第十二次 会议于 2023 年 8 月 8 日（星期二）在公司会议室以现场的方式召开。会议通知 已于 2023 年 7 月 29 日通过电话、邮件的方式送达各位监事。本次会议应出席监 事 3 人，实际出席监事 3 人。 会议由监事会主席胡富苗先生主持，会议召开符合有关法律、法规、规章和 《公司章程》的规定。出席会议的监事对各项议案进行了认真审议并做出了如下 决议： 证券代码：301096 证券简称：百诚医药 公告编号：2023-026 杭州百诚医药科技股份有限公司 第三届监事会第十二次会议决议公告 （二）审议通过《关于<2023 年半年度募集资金存放与使用情况专项报告> 的议案》 经审核，监事会认为：公司编制的 2023 年半年度募集资金存放与使用情况 的专项报告符合相关法律法规、规范性文件的规定，在所有重大方面真实反映 了 2023 年上半年公司募集资金存放与使用的实际情况。 表决结果：3 票同意，0 票反对，0 票弃权。 ...

杭州百诚医药科技股份有限公司 | 项 目 | | 序号 | 金 额 | | --- | --- | --- | --- | | | 永久补充流动资金 | C3 | 36,387.00 | | | 暂时补充流动资金 | C4 | 45,000.00 | | 截至期末累计发生额 | 项目投入 | D1=B1+C1 | 49,256.91 | | | 利息收入净额 | D2=B2+C2 | 2,774.41 | | | 永久补充流动资金 | D3=B3+C3 | 72,774.00 | | 应结余募集资金 | | E=A-D1+D2- D3-C4 | 22,086.51 | | 实际结余募集资金 | | F | 22,086.51 | | 差异 | | G=E-F | 0 | 2023年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 杭州百诚医药科技股份有限公司（以下简称"公司"或"本公司"）经中国证券 监督管理委员会《关于同意杭州百诚医药科技股份有限公司首次公开发 ...

证券代码：301096 证券简称：百诚医药 杭州百诚医药科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |--------------|-----------------------|-------------|----------------| | | | | 编号：2023-004 | | 投资者关系活 | | | | | | 特定对象调研 | □分析师会议 | | | 动类别 | | | | | | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 现场参观 □其他（电话） 参与单位名称 | --- | |------------------------------------------------------| | 湘财基金、英大信托、慎知资产、宏道投资、天弘基金、华 | | 安基金、易方达基金、彬元资本、华安证券、中泰证券、长 | | 城证券、长江证券等 30 家机构 50 名参与人员。 | 及人员姓名 时间 2023 年 6 月 8 日-6 月 13 日 地点 公司会议室 上市公司接待 董事长、总经理楼金芳 人员姓名 董事、副总经理、董事 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥160,921,094.30, representing a 67.97% increase compared to ¥95,802,322.64 in the same period last year[4] - Net profit attributable to shareholders was ¥35,068,583.71, up 79.56% from ¥19,529,827.85 year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥34,554,752.28, reflecting a significant increase of 115.38% compared to ¥16,043,324.96 in the previous year[4] - The basic earnings per share rose to ¥0.32, a 77.78% increase from ¥0.18 in the same period last year[4] - The total operating revenue for Q1 2023 was CNY 160,921,094.30, a significant increase of 68% compared to CNY 95,802,322.64 in Q1 2022[16] - The net profit for Q1 2023 reached CNY 35,109,632.51, up 80% from CNY 19,498,070.83 in the same period last year[17] - The earnings per share (EPS) for Q1 2023 was CNY 0.32, compared to CNY 0.18 in Q1 2022, reflecting a 78% increase[17] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥3,246,045,079.45, a 10.80% increase from ¥2,929,704,604.58 at the end of the previous year[4] - The total assets increased to CNY 3,246,045,079.45, compared to CNY 2,929,704,604.58 at the end of Q1 2022, reflecting a growth of approximately 11%[16] - The total liabilities rose to CNY 712,936,666.80, up from CNY 447,445,307.03, marking an increase of about 59%[16] - The total current assets amount to 1,755,101,778.18 yuan, an increase from 1,609,891,239.32 yuan at the beginning of the year[14] - The company has a total of 132,009,767.53 yuan in contract assets[14] Cash Flow - The net cash flow from operating activities improved significantly to -¥3,367,415.62, a 89.81% increase compared to -¥33,055,022.37 in the previous year[4] - The company's cash flow from operating activities showed a positive trend, indicating improved liquidity and operational efficiency[18] - Operating cash inflow for the current period was $156,711,271.26, compared to $104,198,451.75 in the previous period, representing a 50.4% increase[19] - Net cash outflow from operating activities was -$3,367,415.62, an improvement from -$33,055,022.37 in the previous period[19] - Cash inflow from financing activities totaled $250,000,000.00, with a net cash inflow of $247,293,154.72, a significant recovery from -$240,411,585.24 in the previous period[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,106[10] - The largest shareholder, Shao Chunnan, holds 18.72% of shares, totaling 20,250,000 shares[10] - The second largest shareholder, Lou Jinfang, holds 12.48% of shares, totaling 13,500,000 shares[10] Expenses - The company experienced a 116.60% increase in management expenses, totaling ¥30,143,084.38, primarily due to the amortization of equity incentive expenses granted in June 2022[8] - Research and development expenses for Q1 2023 were CNY 44,638,654.42, slightly higher than CNY 44,014,040.32 in Q1 2022, demonstrating continued investment in innovation[16] Contract Liabilities - The company reported a significant increase in contract liabilities to CNY 86,171,587.59, up from CNY 62,612,015.80, indicating strong future revenue commitments[16] - The company's contract liabilities increased by 37.63% to ¥86,171,587.59, driven by new customer orders[7] Cash and Equivalents - Cash and cash equivalents at the end of the period are 1,281,825,787.43 yuan, up from 1,238,789,220.70 yuan at the beginning of the year[14] - The net increase in cash and cash equivalents for the current period was $34,640,839.10, compared to a decrease of -$380,966,463.46 in the previous period[20] - The ending balance of cash and cash equivalents was $1,245,708,720.63, down from $1,628,035,047.39 in the previous period[20] Audit Status - The company’s first quarter report was not audited[21]

证券代码：301096 证券简称：百诚医药 杭州百诚医药科技股份有限公司 投资者关系活动记录表 编号：2023-003 二、问答环节 1、问：尊敬的董事长您好，请教公司在中药研究方面的布 局 以及盈利模式，盈利前景如何？ 您好！公司在中药方面进行研发布局，成立了公司中药天然 药物研发中心，主要从事中药新药、经典名方、同名同方、 院内制剂及大健康产品（保健品、特医食品、医疗器械等） 的研究转化及开发。盈利模式主要有受托服务和技术成果转 化，盈利前景比较看好。谢谢。 2、问：您好，请问下中药管线目前的情况和未来的发展谢 谢。 您好！主要有中药新药、经典名方、同名同方、院内制剂及 大健康产品（保健品、特医食品、医疗器械等）的研究转化 | 及开发，目前有多个产品研发中。未来中药的研发将是公司 | | --- | | 收入和利润新的增长点。谢谢。 | | 3、问：公司如何看待 CRO 行业在国内的发展现状和成长潜 | | 力？ | | 您好，从国内来看，随着全球医药外包转移、国内外包需求 | | 释放、原研药数量的增加以及医疗卫生费用日益增长而带来 | | 的控费需求等趋势变化，我国 CRO 行业成长空间大，市场竞 | ...

Financial Performance - The company's revenue for 2022 was CNY 607,410,539.16, representing a 62.27% increase compared to CNY 374,311,815.33 in 2021[22]. - The net profit attributable to shareholders for 2022 was CNY 194,163,970.20, a 74.78% increase from CNY 111,088,253.50 in 2021[22]. - The net cash flow from operating activities reached CNY 259,413,420.62, up 78.38% from CNY 145,424,030.12 in 2021[22]. - Basic earnings per share for 2022 were CNY 1.80, a 31.39% increase from CNY 1.37 in 2021[22]. - The company achieved a revenue of CNY 607.41 million in 2022, representing a year-on-year growth of 62.27%[101]. - The net profit attributable to shareholders reached CNY 194.16 million, an increase of 74.78% compared to the previous year[101]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a year-over-year growth of 20%[188]. - The company anticipates a revenue growth forecast of 20% for the upcoming fiscal year, driven by new product launches and market expansion strategies[161]. Research and Development - The company has a focus on research and development of new products and technologies, although specific figures are not provided in the available content[3]. - The company’s R&D expenses amounted to CNY 166.07 million, reflecting a 104.68% increase year-on-year, indicating a strong commitment to innovation[102]. - The company is currently developing 8 innovative drug projects targeting various pathways, with BIOS-0618 having received clinical approval and entering Phase I trials[61]. - The company is focusing on 8 innovative drug projects, all classified as Class 1 new drugs, targeting areas such as neuropathic pain and tumors, indicating a broad market potential[90]. - The company has established a comprehensive drug R&D and production service platform, integrating pharmaceutical research, clinical trials, and custom production[51]. - The company is focused on enhancing its research and development capabilities to innovate new technologies and products[180]. - The company is investing 200 million yuan in new technology for drug development, which is anticipated to improve efficiency by 25%[188]. Market Expansion and Strategy - Future plans and development strategies are outlined, with a caution for investors regarding potential risks[3]. - The company plans to enhance its market expansion efforts in response to the increasing demand for CRO services driven by the aging population and healthcare reforms in China[36]. - The company aims to retain sales rights sharing in contracts with clients, ensuring stable revenue through profit-sharing during the drug's effective lifecycle[57]. - The company plans to increase its market presence by expanding its marketing channels and targeting both domestic and international markets, particularly in traditional Chinese medicine and biopharmaceuticals[148]. - The company is exploring new market opportunities to expand its product offerings and reach[194]. - The company is actively pursuing mergers and acquisitions to enhance its market position and expand its product offerings[161]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[164]. Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the meeting[3]. - The company is committed to maintaining a robust governance structure, as indicated by the presence of the board and supervisory committees[3]. - The financial report is subject to audit by a registered accounting firm, ensuring transparency and accountability[9]. - The company has established a comprehensive quality management system to ensure data authenticity and reliability, including independent QA department oversight[96]. - The company has no significant discrepancies between its governance practices and the regulations set forth by the China Securities Regulatory Commission[169]. - The company maintains complete independence in assets, personnel, finance, organization, and business operations from its controlling shareholders[170]. Operational Efficiency - The company has established a robust internal management system to enhance operational efficiency and protect shareholder interests[169]. - The company has a stable and dedicated R&D team led by experienced professionals, enhancing project initiation and industry trend forecasting capabilities[99]. - The company is committed to continuous improvement in its management systems to handle the increased scale of operations and maintain efficiency[152]. - The company has implemented a stock incentive plan for 197 executives and core employees, which has resulted in significant share-based payment expenses[156]. - The company is focused on optimizing its human resource management system to maximize employee value and overall profitability[156]. Risk Management - The company has outlined its risk management strategies in the management discussion section, which is crucial for future growth[3]. - The company recognizes the risks associated with drug development failures and long development cycles, and it is implementing strategies to mitigate these risks through talent acquisition and process optimization[150][152]. - The company acknowledges the potential for business fluctuations due to changes in industry policies, market competition, and customer demand[154]. Investment and Financial Management - The company raised a total of ¥2,152,516,693.20 from its initial public offering, with a net amount of ¥1,863,430,088.41 after deducting issuance costs[136]. - The company’s investment activities resulted in a net cash outflow of CNY 690.87 million, a 175.07% increase in outflow compared to the previous year[102]. - The company has ongoing significant non-equity investments, including a project with an investment amount of ¥225,800,000 for research and testing[131]. - The company has approved the proposal to change its registered capital, address, and type, along with amending the articles of association[198]. Customer and Market Metrics - User data indicates a steady growth in customer base, contributing to an overall revenue increase of 15% year-over-year[161]. - User data indicates a growth in active users, reaching 2 million, which is a 15% increase compared to the previous year[188]. - The company has secured a significant number of new orders, indicating strong demand for its products in the market[161]. Product Development - New product development includes the launch of three innovative drug formulations, expected to contribute an additional 300 million yuan in revenue[188]. - The company is developing multiple new drugs targeting various diseases, including a first-class new drug for cancer and a new inhalation drug for asthma[121].